Gabay, Cem <br/><br/>
Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes.  [electronic resource] 

 -  Arthritis research & therapy  04 2020 
 - 70 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1478-6362 
<br/><br/><label>Standard No.: </label>10.1186/s13075-020-02163-6  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adalimumab--therapeutic use<br/>Adult<br/>Aged<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Arthritis, Rheumatoid--blood<br/>Biomarkers--blood<br/>Bone Remodeling--drug effects<br/>C-Reactive Protein--analysis<br/>Cardiovascular Diseases--blood<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Male<br/>Matrix Metalloproteinase 3--blood<br/>Middle Aged<br/>Prospective Studies<br/>Treatment Outcome